
Curigen Pharmaceuticals LLP
About Curigen Pharmaceuticals LLP
Data last updated:
Curigen Pharmaceuticals LLP is a limited liability partnership (LLP) based in Surat, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 08 June 2018 and has been in existence for over 8 years.
The LLP is registered with the Registrar of Companies (ROC), Ahmedabad, under LLPIN AAM-7893. Its GSTIN is 24ADRFS5465M1Z9 (Gujarat).
The LLP has a total obligation of contribution of ₹25 Lakh. It is led by designated partners including Krishna Sanjaykumar Maniya and Sanjaykumar Popatbhai Maniya.
Its latest statement of accounts is for the year ended 31 March 2025. The registered office is at Surat, Gujarat.
As per the financials filed for FY 2025, the LLP reported a revenue of ₹5.36 Cr, reflecting significant growth compared to the previous year. For the same year it recorded a net profit of ₹4.26 Lakh (net margin 0.8%) and EBITDA of ₹9.7 Lakh (EBITDA margin 1.8%). Revenue has grown at a compounded annual rate (CAGR) of 100% over three years and 107% over five years.
As per MCA filings, the LLP has open charges of ₹1 Cr on record.
Company details
Contact details
Curigen Pharmaceuticals LLP's registered office is in Surat, Gujarat.
- Registered AddressOffice No. 105 First Floor Raghuveer Platinum, Kumbhariya, Surat, Gujarat, India – 395010
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Curigen Pharmaceuticals LLP
FY 2025 filings availableCurigen Pharmaceuticals LLP reported revenue of ₹5.36 Cr (up 515% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 107% over five years, including 515% growth in the latest year. EBITDA rose 727% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Statement of Account and Solvency | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Income and Expenditure | |||||
| Turnover | |||||
| Other Income | |||||
| Total Income | |||||
| Purchases and Direct Costs | |||||
| Personnel Expenses | |||||
| Administrative Expenses | |||||
| Interest | |||||
| Depreciation | |||||
| Total Expenses | |||||
| Profit Before Tax | |||||
| Tax | |||||
| Profit After Tax | ₹4.26 Lakh | ||||
| Profit Transferred to Partners | |||||
| Assets and Liabilities | |||||
| Partners' Contribution | |||||
| Reserves and Surplus | |||||
| Secured Loans | |||||
| Unsecured Loans | |||||
| Trade Payables | |||||
| Other Liabilities and Provisions | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Loans and Advances | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Statement of Account and Solvency | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| Net Profit Margin | 0.8% | ||||
| Return on Partners' Funds | |||||
| Return on Assets | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Debt to Partners' Funds | |||||
| Interest Coverage | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Turnover Growth | |||||
| Profit Growth | |||||
To see the full financial statements and ratios of Curigen Pharmaceuticals LLP, buy the company report.
Designated partners of Curigen Pharmaceuticals LLP
Curigen Pharmaceuticals has 3 current designated partners and 2 former designated partners. Current designated partners are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Krishna Sanjaykumar Maniya Also directs: Long-D Hospitality LLP, PP Maniya Healthcare LLP, Satyug Corporate Consultancy Private Limited and 1 more | Designated Partner | 08 Jun 2018 | 8 Years 5 Months | Current |
| Sanjaykumar Popatbhai Maniya Also directs: Long-D Hospitality LLP, PP Maniya Healthcare LLP, PP Maniya Hospital Private Limited and 3 more | Designated Partner | 19 Jul 2025 | 1 Years 3 Months | Current |
| Nilesh Popatbhai Maniya Also directs: PP Maniya Healthcare LLP, PP Maniya Hospital Private Limited, PP Maniya Pharmacy LLP and 2 more | Designated Partner | 09 Oct 2023 | 3 Years 1 Months | Current |
Peer comparison
Curigen Pharmaceuticals LLP is compared with the 10 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Cardo Pharma Private Limited | ₹5.37 Cr (FY 2025) | 4.0% | Patna, Bihar, India | |||
| Upsilon Pharmaceuticals Health Care Private Limited | ₹5.37 Cr (FY 2024) | 3.0% | Gwalior, Madhya Pradesh, India | |||
| Jyoti Vishnu Pharma Private Limited | ₹5.37 Cr (FY 2025) | 3.0% | Hyderabad, Telangana, India | |||
| JPM Pharma & Chemicals Private Limited | ₹5.36 Cr (FY 2024) | 80.0% | Mumbai, Maharashtra, India | |||
| Aurocare Lifesciences Private Limited | ₹5.36 Cr (FY 2024) | 32.0% | Ahmedabad, Gujarat, India | |||
| Curigen Pharmaceuticals LLPthis company | ₹5.36 Cr (FY 2025) | ₹4.26 Lakh | 0.8% | 515.0% | Surat, Gujarat, India | |
| Siddhakala Print Media and Publications Private Limited | ₹5.36 Cr (FY 2025) | -3.0% | Navi Mumbai, Maharashtra, India | |||
| Krishgir Pharmaceuticals Private Limited | ₹5.35 Cr (FY 2025) | -18.0% | Chandigarh, India | |||
| Brochem Healthcare Private Limited | ₹5.34 Cr (FY 2023) | 19.0% | Navi Mumbai, Maharashtra, India | |||
| Sahyog Creations Private Limited | ₹5.34 Cr (FY 2024) | Solapur, Maharashtra, India | ||||
| Procyon Pharmaceuticals Private Limited | ₹5.34 Cr (FY 2025) | 19.0% | Madurai, Tamil Nadu, India |
To see the full peer comparison of Curigen Pharmaceuticals LLP, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 25 Jun 2024 | 100961464 | Bank of India | ₹1 Cr | Open |
Total charge records: 1 View all charges
Legal cases
No court or tribunal cases involving Curigen Pharmaceuticals LLP are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Curigen Pharmaceuticals LLP; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Curigen Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24ADRFS5465M1Z9 | Gujarat | Active | 12 Oct 2018 |
To see the full GST registrations and return filing status of Curigen Pharmaceuticals LLP, buy the company report.
Recent activity
Curigen Pharmaceuticals LLP has 6 designated partner changes on record since 2018: 4 appointments and 2 cessations. The latest: Sanjaykumar Popatbhai Maniya was appointed as Designated Partner on 19 Jul 2025.
Frequently asked questions
Curigen Pharmaceuticals is an active limited liability partnership based in Surat, Gujarat, India. The LLP works in drug formulation and development, within the pharma industry. It was incorporated on 08 June 2018 (8+ years old) and is registered under LLPIN AAM-7893.
Curigen Pharmaceuticals has 3 current designated partners:
- Krishna Sanjaykumar Maniya - Designated Partner
- Sanjaykumar Popatbhai Maniya - Designated Partner
- Nilesh Popatbhai Maniya - Designated Partner
The latest financial statements of Curigen Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 31 March 2025. Year-wise statements from FY 2019 are in the company report.
The GSTIN of Curigen Pharmaceuticals is 24ADRFS5465M1Z9, registered in Gujarat.
The LLPIN (Limited Liability Partnership Identification Number) of Curigen Pharmaceuticals is AAM-7893. It is issued by the Ministry of Corporate Affairs and uniquely identifies the LLP in India.
Curigen Pharmaceuticals was incorporated on 08 June 2018, making it 8+ years old. It is registered with the Registrar of Companies, Ahmedabad.
The peers of Curigen Pharmaceuticals by revenue are Cardo Pharma Private Limited, Upsilon Pharmaceuticals Health Care Private Limited, Jyoti Vishnu Pharma Private Limited, JPM Pharma & Chemicals Private Limited, Aurocare Lifesciences Private Limited and 5 more, all in the Pharma industry (Formulations, Pharmaceuticals).
Sanjaykumar Popatbhai Maniya was appointed as Designated Partner on 19 Jul 2025. Nilesh Popatbhai Maniya was appointed as Designated Partner on 09 Oct 2023. Janak Gopalbhai Lathia was appointed as Designated Partner on 08 Mar 2021. Curigen Pharmaceuticals has 6 designated partner changes on record in total.
The registered office of Curigen Pharmaceuticals is at Office No. 105 First Floor Raghuveer Platinum, Kumbhariya, Surat, Gujarat, India – 395010.
Curigen Pharmaceuticals operates in the pharma industry, in the drug formulation and development segment.
Curigen Pharmaceuticals has open charges of ₹1 Cr and no satisfied charges on record as per latest MCA filings.

